Parker-Hannifin Corp (PH) Stock News

Rosen Law Firm has filed a class action lawsuit on behalf of investors in Park Ha Biological Technology Co., Ltd. (NASDAQ: PHH, BYAH) for the period between December 27, 2024 and July 8, 2025. The lawsuit alleges that defendants made materially false statements and failed to disclose that Park Ha was subject to a fraudulent stock promotion scheme involving social media misinformation, impersonated financial professionals, and artificially manipulated trading activity. The firm is seeking investors who purchased securities during the class period to join the action, with a lead plaintiff deadline of September 28, 2026.

Rosen Law Firm has filed class action lawsuits against Park Ha Biological Technology Co., Ltd. (NASDAQ: PHH, BYAH) on behalf of investors who purchased securities between December 27, 2024 and July 8, 2025. The lawsuit alleges that defendants made materially false statements and failed to disclose a fraudulent stock promotion scheme involving social media misinformation, artificially low public float, and manipulated trading activity. The deadline to serve as lead plaintiff is September 28, 2026.

Rosen Law Firm has filed class action lawsuits against Park Ha Biological Technology Co., Ltd. (PHH, BYAH) for securities fraud involving false statements and undisclosed fraudulent stock promotion schemes during December 2024-July 2025. A separate lawsuit targets GRAIL, Inc. (GRAL) with an August 4, 2026 deadline for investors to secure counsel. Both cases allege material misstatements and failure to disclose adverse facts affecting stock prices.

Law firm Kirby McInerney LLP is investigating potential securities fraud claims against Alnylam Pharmaceuticals following the company's announcement on July 30, 2026, that it lowered TTR product sales guidance by approximately $200 million due to normalization of growth in the ATTR-CM market after satisfying pent-up demand. The stock fell 28% ($81.14 per share) to $205.48 on the news.

LEPAS, a mid-to-premium NEV brand under Chery Auto, has launched the LEPAS L8 PHEV to global markets. The vehicle features the LEPAS Super Hybrid system with 45.79% thermal efficiency, 1,300km driving range, and ultra-low fuel consumption of 2.38L/100km. It includes Level 2 ADAS with 540° panoramic imaging and comprehensive safety features including 10 airbags and IP68/IPX9K battery protection.

LEPAS, a mid-to-premium NEV brand under Chery Auto, has launched the LEPAS L8 PHEV globally. The vehicle features the LEPAS Super Hybrid system with 45.79% thermal efficiency, achieving 2.38L/100km fuel consumption and 1,300km range. It incorporates Leopard Aesthetics design philosophy, Level 2 ADAS technology, and comprehensive safety features including 10 airbags and IP68/IPX9K battery protection.

LEPAS, Chery Auto's mid-to-premium NEV brand, unveiled the LEPAS L8 PHEV for global markets. The vehicle features advanced hybrid technology with 45.79% thermal efficiency, 2.38 L/100km fuel consumption, and 1,300km total range. It incorporates 'Leopard Aesthetics' design philosophy, Level 2 ADAS with 540° panoramic vision, and comprehensive safety features including triple-protection battery system.

LEPAS, Chery Auto's mid-to-premium NEV brand, has launched the LEPAS L8 PHEV globally. The vehicle features the LEPAS Super Hybrid System with a 45.79% thermal efficiency, combined fuel consumption of 2.38 l/100km, and a total range of up to 1,300 kilometers. It includes advanced safety features with Level 2 ADAS and distinctive 'Leopard Aesthetics' design language.

LEPAS, Chery Auto's mid-to-premium NEV brand, has launched the LEPAS L8 PHEV globally, featuring advanced hybrid technology with 45.79% thermal efficiency, ultra-low fuel consumption of 2.38L/100km, and up to 1,300km range. The vehicle combines 'Leopard Aesthetic' design philosophy with Level 2 ADAS safety features and premium interior amenities.

LEPAS, a mid-to-premium NEV brand under Chery Auto, has launched the LEPAS L8 PHEV globally. The vehicle features advanced hybrid technology with 45.79% thermal efficiency, a combined fuel consumption of 2.38L/100km, and a range of up to 1,300km. It includes comprehensive safety features with Level 2 ADAS, 10 airbags, and intelligent driver assistance systems.

LEPAS, a mid-to-premium NEV brand under Chery Auto, unveiled the LEPAS L8 PHEV globally, featuring advanced hybrid technology with 45.79% thermal efficiency, 2.38L/100km fuel consumption, and up to 1,300km range. The vehicle combines 'Leopard Aesthetics' design philosophy with Level 2 ADAS and comprehensive safety features, targeting consumers seeking intelligent and elegant mobility solutions.

LEPAS, a mid-to-premium new energy vehicle brand under Chery Auto, officially launched the LEPAS L8 PHEV to global markets. The vehicle features advanced hybrid technology with 45.79% thermal efficiency, 97.6% transmission efficiency, achieving 2.38L/100km fuel consumption and 1300km NEDC range. It incorporates 'Leopard Aesthetic' design philosophy, L2-level autonomous driving assistance, comprehensive safety features including 10 airbags and triple battery protection, and premium interior amenities.

LEPAS, Chery Auto's mid-to-premium NEV brand, has launched the LEPAS L8 PHEV globally. The vehicle features the LEPAS Super Hybrid system with 45.79% thermal efficiency, achieving 2.38 L/100km fuel consumption and 1,300km range. It includes Level 2 ADAS, distinctive 'Leopard Aesthetics' design, and comprehensive safety features including a cage-type body and triple-level battery protection.

Chery Auto's premium NEV brand LEPAS has launched the L8 PHEV globally, featuring advanced hybrid technology, intelligent driving functions, and distinctive 'Leopard Aesthetics' design. The vehicle achieves 45.79% thermal efficiency, 100km fuel consumption of 2.38L, and up to 1,300km combined range with Level 2 ADAS and comprehensive safety systems.

ALPHEA, a platform building infrastructure for AI agents, has secured $5 million in strategic funding from investors including MH Ventures, IBC Ventures, Titan Ventures, and Becker Ventures. The funding will accelerate product development and expand ALPHEA's global node ecosystem, enabling AI agents to run, collaborate, store data, and settle value efficiently in a distributed cloud environment designed specifically for autonomous AI operations.

Pharvaris director Johannes Schikan sold 37,600 shares worth $1.3 million in late June 2026, representing 10.66% of his direct holdings. The sale occurred under a Rule 10b5-1 trading plan following a 96.5% one-year stock price appreciation. Shortly after, the FDA accepted the company's New Drug Application for its lead drug deucrictibant for hereditary angioedema treatment, though the stock has remained relatively flat since the announcement.

ALPHEA, an AI infrastructure platform, has raised $5 million in strategic funding from investors including MH Ventures, IBC Ventures, Titan Ventures, and Becker Ventures. The funding will accelerate development of ALPHEA's AI-native distributed cloud designed specifically for autonomous agents, with plans to expand its global node ecosystem and improve developer tools.

Jyong Biotech reaffirms its strategic focus on global licensing partnerships to address the growing BPH market. The company highlights that the global BPH patient population reached 112.5 million in 2021 and is projected to grow to 150-156 million by 2035, with the market size expected to grow from $13 billion in 2025 to $22-22.6 billion by 2035. Jyong Biotech's lead candidate Botreso® (API-1) has completed four Phase III clinical trials and aims to address unmet medical needs caused by severe side effects of existing treatments.

IXJ and RSPH are two healthcare ETFs with different strategies: IXJ uses cap-weighted global exposure with larger pharmaceutical companies, offering higher dividends (1.47%) and lower volatility (beta 0.52), while RSPH employs equal-weighting of S&P 500 healthcare stocks, providing stronger 1-year returns (21.01% vs 18.29%) but higher risk (beta 0.81). The choice depends on investor goals—IXJ suits conservative/income-focused investors, while RSPH appeals to growth-oriented investors willing to accept volatility.

Rosen Law Firm is reminding Phreesia, Inc. investors who purchased stock between May 8, 2025 and March 30, 2026 of the July 13, 2026 deadline to serve as lead plaintiff in a securities class action. The lawsuit alleges that Phreesia made false statements and concealed material facts regarding slowing demand and weakened pharmaceutical marketing commitments in its Network Solutions segment, resulting in investor damages.

Defiance ETFs has launched the Defiance Photonics UCITS ETF (ticker: PHOT), Europe's first photonics-focused ETF. The fund invests in companies developing and commercializing photonics technology, which uses light instead of electricity for data transmission and processing. This is Defiance's fifth UCITS ETF since entering the European market in early 2026. The ETF is listed on LSE and Borsa Italiana with plans for Xetra listing, and carries a total expense ratio of 0.69%.

Defiance ETFs has launched the Defiance Photonics UCITS ETF (PHOT), Europe's first photonics-focused ETF. The fund provides investment exposure to companies developing, manufacturing, and commercializing photonic technologies—optical hardware that uses light instead of electricity for data transmission. With a 0.69% total expense ratio, the ETF is listed on the London Stock Exchange and Borsa Italiana, with plans for Xetra listing. This is Defiance's fifth UCITS product since entering the European market earlier in 2026.

Defiance ETFs has launched the Defiance Photonics UCITS ETF (ticker: PHOT), Europe's first photonics-focused ETF. The fund provides exposure to companies developing and commercializing photonics technology for data transmission and processing. This is Defiance's fifth UCITS ETF launch in Europe this year, with the company accumulating $162.57 million in AUM across its UCITS product line. The ETF is listed on London Stock Exchange and Borsa Italiana, with Xetra listing planned.

Defiance ETFs has launched the Defiance Photonics UCITS ETF (PHOT), Europe's first photonics-focused ETF. The fund targets companies developing, manufacturing, and commercializing photonic technologies that use light instead of electricity for data transmission and processing. This is Defiance's fifth UCITS product since entering the European market in early 2026, with the fund listed on London Stock Exchange and Borsa Italiana.

Defiance ETFs has launched the Defiance Photonics UCITS ETF (ticker: PHOT), Europe's first photonics-focused ETF. The fund provides exposure to companies involved in developing, manufacturing, and commercializing photonic technology—optical hardware that uses light instead of electricity to generate, transmit, and process data. This is Defiance's fifth UCITS ETF launch since entering the European market in early 2026, with the fund listed on London Stock Exchange and Borsa Italiana.

Bernstein Liebhard LLP has announced an investigation into whether certain directors and officers of Phreesia, Inc. breached their fiduciary duties to the company. The investigation targets shareholders who purchased shares prior to May 8, 2025. The law firm is seeking affected shareholders to discuss their legal rights and options.

The Schall Law Firm is seeking investors who purchased Phreesia, Inc. securities between May 8, 2025 and March 30, 2026 to join a class action lawsuit alleging securities fraud. The company allegedly made false and misleading statements regarding its long-term growth outlook and fiscal year 2027 projections, particularly regarding pharmaceutical marketing commitments as a growth driver for its Network Solutions segment.

The article compares two healthcare ETFs: Invesco's IBBQ and State Street's XPH. IBBQ offers lower costs (0.19% expense ratio), broader diversification (253 holdings), and higher dividend yield (0.80%), making it better for long-term investors. XPH delivered stronger 1-year returns (63.90% vs 57.20%) with less volatility but charges higher fees (0.35%) and holds only 65 positions. Both funds have significantly underperformed the S&P 500 over five years, reflecting the challenges of biotech and pharmaceutical investing.

The article compares two healthcare ETFs: VanEck Biotech ETF (BBH) with 25 concentrated holdings and State Street SPDR S&P Pharmaceuticals ETF (XPH) with 65 diversified holdings. Both charge identical 0.35% expense ratios and offer 0.50% dividend yields, but XPH delivered significantly higher 1-year returns (64.30% vs 33.30%) and lower volatility, making it potentially more suitable for beginners seeking diversification.

A securities class action lawsuit has been filed against Photronics, Inc. (NASDAQ: PLAB) on behalf of investors who purchased securities between December 10, 2025 and May 27, 2026. The lawsuit alleges the company made materially false and misleading statements regarding business operations, growth prospects, and financial stability, causing securities to trade at artificially inflated prices. Investors suffered significant losses when the truth was disclosed.